The Gamaleya Center of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) announced the publication of the results of the third phase of clinical trials of the Sputnik V coronavirus vaccine in the medical journal The Lancet.
As specified, the effectiveness of the drug against the disease was 91.6% after analyzing data from 19,866 volunteers. At the same time, the indicator among the group of volunteers over 60 years old was 91.8%.
“The publication of an international peer review of Sputnik V clinical trials is a great success in the global fight against the pandemic. The safety and high efficiency of the Russian vaccine is confirmed by the presented reliable scientific data, and I am glad to congratulate the entire team of the V. Gamaleas with this outstanding achievement,” said Alexander Gintsburg, director of the Gamaleya Center.
According to the head of the RDIF Kirill Dmitriev, the published article proves the effectiveness and safety of the Sputnik V vaccine created in Russia. He stressed that only three drugs in the world have an efficiency exceeding 90%, and the Russian development is superior to others.
“The vaccine is 100% effective in preventing serious illness or death, and this is the most important parameter. Even after the first injection of this two-component vaccine, the level of protection against the disease was 87.6%,” said MD, professor, director of the Center for Vaccines and Immunotherapy at the Wistar Hildegund Ertl Institute, adding that Sputnik V is superior in this indicator to the products of AstraZeneca and Johnson & Johnson.
It is emphasized that as a result of the studies, no serious side effects of the vaccine administration were revealed; the humoral immune response was developed in more than 98% of the volunteers. In addition, all vaccinated individuals developed a cellular immune response.
At the same time, the level of antibodies that neutralize COVID-19 in those vaccinated with Sputnik V turned out to be 1.3-1.5 times higher than in those who had been ill.
“This vaccine has proven to be very effective and highly immunogenic for different age groups,” said MD, director of research at the National Institute for Health and Medical Research (Inserm) in France.
The first coronavirus vaccine in Russia and the world was registered on August 11. Sputnik V was developed by specialists from the Gamaleya Center. Large-scale vaccination of the population against COVID-19 began in Russia on January 18. The need for this was stated by Russian President Vladimir Putin, who called the center’s vaccine the best in the world.